Glyrova CV 10 Tablet is a combination pharmaceutical formulation containing Rosuvastatin 10 mg and Clopidogrel 75 mg, indicated for the management of cardiovascular conditions requiring both lipid-lowering and antiplatelet therapy. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) and triglycerides while moderately increasing high-density lipoprotein cholesterol (HDL-C). This lipid-modifying effect contributes to the prevention of atherosclerotic plaque progression and reduces the risk of cardiovascular events. Clopidogrel, a thienopyridine class antiplatelet agent, inhibits platelet aggregation by irreversibly blocking the P2Y12 component of ADP receptors on platelet surfaces, thereby reducing the risk of thrombotic events such as myocardial infarction and ischemic stroke. The combined action of Rosuvastatin and Clopidogrel in Glyrova CV 10 Tablet is particularly beneficial for patients with established coronary artery disease, peripheral arterial disease, or those at high risk of cardiovascular complications. It is essential to use this medication under medical supervision, with regular monitoring of lipid profiles, liver function tests, and platelet activity to ensure efficacy and safety. Patients should be advised regarding potential side effects, including myopathy, bleeding tendencies, and hypersensitivity reactions, and to report any unusual symptoms promptly.